Clinical snapshot — for veterinary teams
- Active ingredient / class: bedinvetmab — anti–nerve growth factor (anti-NGF) monoclonal antibody (biologic)
- Indication: control of pain associated with osteoarthritis in dogs
- Administration: monthly subcutaneous injection, in-clinic, dosed by weight
- Clearance: via normal protein degradation — not liver/kidney metabolized, which is part of its appeal for older, comorbid OA patients
- Monitoring windows that matter: first week post-injection (most reported adverse events cluster here; many within 24 hours); ongoing mobility/response and any new neurologic signs
- Regulatory note: FDA “Dear Veterinarian Letter” (Dec 2024) on reported adverse events, and a Feb 2025 label update adding a Client Information Sheet and an expectation that clinicians discuss benefits, risks, and what to monitor with owners before dosing
- Counsel clients on: what improvement to expect, and which post-injection signs warrant a call (see below); hypersensitivity is possible; concurrent NSAID use not fully evaluated
Plain answer for owners who landed here: Many dogs get good osteoarthritis pain relief from Librela, a monthly injection. Side effects are uncommon, but the FDA has highlighted reports of problems — mostly neurological signs such as wobbliness (ataxia), and in some cases worsening mobility — and updated the label so your vet discusses what to watch for. Contact your vet promptly if you notice stumbling, weakness, seizures, increased thirst or urination, or any decline after an injection.
What it’s used for — and why clients call about it
Librela is the first monoclonal antibody approved in the US for canine osteoarthritis pain — a monthly injection that, for many dogs, restores mobility that NSAIDs alone weren’t managing, without liver/kidney metabolism. It’s also a drug the regulatory picture has made more follow-up-dependent: after post-market adverse-event reports, the FDA issued a Dear Veterinarian Letter and the label was updated to expect owners be counseled on what to monitor. That means structured post-injection follow-up isn’t just good practice here — it’s aligned with how the product is now meant to be used.
The adverse-event and monitoring profile
In pre-approval studies Librela was considered safe and effective, and global pharmacovigilance across more than 18 million doses characterizes adverse events as rare to very rare. Alongside that, the FDA’s December 2024 communication summarized post-market reports — predominantly neurologic signs (ataxia, seizures, paresis, recumbency) plus urinary incontinence, increased thirst and urination, and in some cases death or euthanasia; ataxia was the most frequently reported sign, and many signs appeared within the first week (a substantial share within the first day). Separately, an EMA-database analysis raised a question about musculoskeletal events and possible accelerated joint changes, echoing signals seen in human anti-NGF trials — an area of ongoing scientific discussion, not settled causation. These are adverse-event reports: they don’t establish that the drug caused each outcome, but they’re why the February 2025 label now includes a Client Information Sheet and a pre-dosing risk discussion. (Sources: FDA Dear Veterinarian Letter, Dec 2024, and AVMA summary; Librela FDA label update, Feb 2025; EudraVigilance analysis, Farrell et al., 2025; Zoetis global pharmacovigilance, 2025.)
The follow-up window that matters
The defining window is the first week after each injection — that’s where the reported adverse events concentrate, with a meaningful share in the first 24 hours. Because Librela is dosed monthly and given in-clinic, every dose opens a fresh monitoring window, and the clinic usually isn’t in the room when signs appear. The second, longer thread is response tracking: is mobility actually improving, holding, or declining over successive months? Both are owner-reported, between-visit information the clinic needs but rarely captures systematically.
What to ask clients at follow-up
After each injection, a focused check covers:
- Any wobbliness, stumbling, weakness, tremors, or seizure activity since the injection? (the neurologic screen the FDA highlighted)
- Any new increase in thirst, urination, or accidents in the house?
- Has your dog’s mobility and comfort improved, stayed the same, or declined?
- Any swelling, hives, or breathing difficulty after the injection? (hypersensitivity)
Captured every cycle, these build exactly the post-administration safety and response record the updated label envisions — and give the vet an early read on whether to continue, adjust, or reassess.
Where compliance breaks down
Two gaps. First, the safety gap: the label now expects owners to be counseled and monitored, but a verbal heads-up at the visit rarely produces structured feedback once the dog is home and signs emerge days later. Second, the response gap: without consistent tracking, a dog who isn’t truly benefiting (or is slowly declining) can keep getting monthly injections by default. Closing both depends on reliable between-visit follow-up — which is hard to staff by hand for every OA patient.
Standardizing this follow-up without adding staff time
This is a strong fit for Nidana Loop, and it maps directly onto the updated label’s intent. After each Librela injection, Loop calls or texts the owner during the critical first-week window to screen for the neurologic and other signs the FDA flagged, captures the responses as a structured note back to the clinic, and flags anything concerning for a vet immediately. It also tracks mobility response month over month, so the decision to continue is evidence-based rather than default. The clinic gets a documented post-injection safety check on every patient, every cycle — without adding a single staff call.
See Loop handle medication follow-up
Loop runs the post-injection safety check-in, monitors response over time, and flags adverse events to the clinic automatically — structured, documented, and hands-off. Book a 20-minute demo → · See how Loop works →
For pet owners
What are the main side effects to watch for? Side effects are uncommon, but the FDA has highlighted reports of mainly neurological signs — wobbliness, weakness, seizures — and sometimes worsening mobility or increased thirst/urination. Contact your vet if you see these.
How is Librela given? As a monthly injection at your veterinary clinic.
Did the label change? Yes — in early 2025 the FDA updated the label so your vet discusses the benefits, risks, and what to monitor, and provides a client information sheet.
Is it safe for older dogs? It isn’t processed by the liver or kidneys, which is part of why it’s used in older dogs — but your vet will weigh the benefits and the monitoring guidance for your individual dog.
This article is general information, not veterinary advice. Adverse-event reports describe events reported after use and do not by themselves establish that the medication caused them. Owners should consult their veterinarian and follow the product’s FDA-approved label and client information sheet.
Sources: FDA Dear Veterinarian Letter (Dec 2024), via AVMA summary; Librela (bedinvetmab) FDA label update (Feb 2025); EudraVigilance musculoskeletal analysis (Farrell et al., 2025); Zoetis global pharmacovigilance study (2025); dvm360; Today’s Veterinary Practice.